Article Text

Download PDFPDF
5PSQ-119 A survey of lactose content in drugs used for hepatitis c treatment
  1. C Salom Garrigues,
  2. A Retamero Delgado,
  3. RM Parés Marimon,
  4. X Sanchez Fresquet,
  5. J Serrais Benavente,
  6. D Ferrández Martí
  1. Hospital d’igualada, Consorci Sanitari de l’anoia, Pharmacy, Igualada, Spain


Background Lactose is widely used as a filler in the manufacture of pharmaceutical tablets and capsules, which should be taken into account to avoid adverse effects in lactose-intolerant patients.

Purpose A survey was conducted to find out the lactose content in several drugs used in the treatment of hepatitis C, in order to select lactose-free drugs as therapeutic options suitable for lactose-intolerant patients.

Material and methods A list of drugs approved or pending approval in Spain for the treatment of hepatitis C was obtained from the webpages of the agencies in Spain (Agencia Española de Medicamentos y Productos Sanitarios) and the European Union (European Medicines Agency). Information about the list of excipients and particularly lactose content was obtained from the product information sheets. Lactose-free medicinal products suitable for lactose-intolerant patients were selected according to viral genotype.

Results There are 16 medicinal products approved for hepatitis C treatment and 1 pending approval in Spain. Ten of these products contained lactose in amounts ranging from 4.94 mg to 156.8 mg per pharmaceutical form unit. A full list of lactose contents is given in the following table.

Abstract 5PSQ-119 Table 1

With regard to direct-acting antivirals, lactose-free sofosbuvir/velpatasvir (Epclusa) should be the first therapeutic option for lactose-intolerant patients of all viral genotypes. Genotype 4 would have paritaprevir/ombitasvir/ritonavir (Viekirax) as second option.

Moreover, when ribavirin treatment is indicated, lactose-free copegus, rebetol solution, ribavirin normon and ribavirin teva should be the therapeutic options in lactose-intolerant patients.

Conclusion General therapeutic options recommended for the treatment of hepatitis C should be adapted in the case of lactose-intolerant patients. Lactose-free medicinal products are available in order to avoid adverse reactions.

No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.